Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled ...
Le Lézard

EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics

EQT Life Sciences is pleased to announce that the LSP Health Economics Fund has exited Vivasure Medical Limited ("Vivasure" or the "Company"), a Galway, Ireland-based company pioneering ...